End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.65 CNY | +1.56% | -4.46% | -8.10% |
04-25 | Byhealth Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-12 | Byhealth Co., Ltd Approves Cash Dividend for the Year 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.10% | 3.67B | D | ||
+8.20% | 7.78B | D+ | ||
+0.34% | 7.38B | C- | ||
+10.20% | 6.52B | - | ||
-14.57% | 1.17B | - | - | |
+8.34% | 934M | - | ||
-42.27% | 879M | B+ | ||
-18.90% | 836M | C+ | ||
-16.45% | 802M | C+ | ||
+0.32% | 711M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300146 Stock
- Ratings Byhealth Co., Ltd